Lead Story Picture
A class of healthy Massachusetts Marlboro smokers wanted Philip Morris to pay for annual scans using low-dose computed tomography, which cost $500 each. (Credit: AP)

Healthy Marlboro Smokers Denied Lung Screening By Mass. Jury

Cigarette giant Philip Morris USA need not pay for annual lung screenings for a large class of currently healthy Marlboro smokers, a Massachusetts federal jury decided Wednesday, according to a Philip Morris spokesman.

  • AG Kane Survives Ouster Vote In Pa. Senate

    A move to oust Pennsylvania Attorney General Kathleen Kane, whose law license has been suspended in the wake of criminal charges, failed to garner the required two-thirds majority in an initial vote in the state’s Senate on Wednesday.

  • Bid To Unseat Hilliard Nixed In GM Ignition Switch MDL

    The New York federal judge presiding over multidistrict litigation over General Motors' deadly ignition switch defect on Wednesday shot down a plaintiffs attorney's bid to eject co-lead counsel Robert C. Hilliard of Hilliard Munoz Gonzales LLP from the litigation, saying that the "sometimes wild" accusations of impropriety are meritless and backed by scant evidence.

  • AIA Reviews Don’t Need To Eye Whole Patents, Fed. Circ. Says

    The Federal Circuit on Wednesday gave its blessing to the Patent Trial and Appeal Board’s policy of conducting partial reviews of patents challenged in America Invents Act inter partes review petitions, rejecting Synopsys Inc.’s argument that the board must review all of the challenged claims.

  • J&J Hit With $13.5M Verdict In 2nd Philly Pelvic Mesh Trial

    A Philadelphia jury returned a $13.5 million verdict against a Johnson & Johnson unit on Wednesday in a case over allegations that the company’s faulty pelvic mesh implants left a woman with near constant pain and discomfort and an inability to have sex.

  • CFTC, Europe Hatch Accord On Clearing Rules

    U.S. and European derivatives regulators on Wednesday announced a long-awaited plan to harmonize key regulations concerning the central clearing of swaps agreements and other instruments, settling years of intense negotiations in which the future of cross-border derivatives trading was at stake.

  • FDA Panel OKs Celltrion Biosimilar Of Janssen's Remicade

    After a grueling debate, an independent panel on Tuesday advised the U.S. Food and Drug Administration to approve Celltrion’s copy of Janssen Biotech’s blockbuster immunosuppressant Remicade, the latest step forward for the emerging biosimilars industry.